Rakovina Therapeutics Inc · TSXV:RKV
Rakovina Therapeutics — Investor Presentation (February 2026)
25 slides from Rakovina Therapeutics's investor presentation, February 2026
Slide 1: Advancing Cancer Care with the Precision & Power of AI
ADVANCING CANCER CARE WITH THE PRECISION & POWER OF AI TSX.V: RKV FSE: 7JO0 Investor Presentation | Q1 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the investors who will pa
Slide 3: Rakovina Therapeutics' Competitive Advantage
RAKOVINA THERAPEUTICS’ COMPETITIVE ADVANTAGE WHAT SETS THIS COMPANY APART VALIDATED AI TECHNOLOGY $18B ADDRESSABLE MARKET BY 20301 Deep Docking platform developed drug licensed to Roche Broad cancer application targeting solid tumors that Pharma in 2015 for over $140M USD in largest Pharma harbor a
Slide 4: The Mission – Improve the Speed and Precision of Oncology Drug Development
THE MISSION – IMPROVE THE SPEED AND PRECISION OF ONCOLOGY DRUG DEVELOPMENT Rakovina Therapeutics is developing DNA Damage Response (DDR) cancer therapies Access to two robust Artificial Intelligence (AI) platforms speed up discovery timelines, increase precision and greatly reduce the risk associate
Slide 5: DNA-Damage Response (DDR) $18B
DNA-DAMAGE RESPONSE (DDR) • DDR pathways repair DNA damage, and when they fail, mutations accumulate and drive cancer formation and growth. • Cancer cells with DDR-mutations rely on backup repair pathways; DDR drugs block these, causing selective cancer cell death. • PARP inhibitors validate DDR as
Slide 6: Investments in DNA-Damage Response by Multi-National Pharmaceutical Corporations
INVESTMENTS IN DNA-DAMAGE RESPONSE BY MULTI-NATIONAL PHARMACEUTICAL CORPORATIONS RECENT DDR TRANSACTIONS Oct 2023 PARP-inhibitor • $1.5B ($169M upfront) • FDA status at signing: phase 1 License Agreement Jun 2022 ATR-inhibitor • $1.2B ($125M upfront) • FDA status at signing: preclinical License Agre
Slide 7: Rakovina Therapeutics' Drug Development Portfolio
RAKOVINA THERAPEUTICS’ DRUG DEVELOPMENT PORTFOLIO Development Stage DDR Pipeline Indication Lead Clinical Discovery Pre-clinical Optimization Trials kt-5000AI (ATR) Solid tumor ENKI AI Platform kt-2000AI (PARP1) Solid tumor Deep Docking AI Platform PARP-resistant JV for co-development kt-3283 (PARP
Slide 8: kt-5000AI: ATR/mTOR Inhibitor
kt-5000AI : ATR/mTOR INHIBITOR A FIRST-IN-CLASS CNS PENETRANT • ATR (ataxia telangiectasia and Rad3-related protein) plays a crucial role in regulating DNA damage repair. • Cancer cells with loss of function of phosphate and tensin homolog (PTEN) are vulnerable to ATR inhibition. • PTEN deficiency a
Slide 9: kt-5000AI: The Prevalence of PTEN in Cancer
kt-5000AI : ATR/mTOR INHIBITOR THE PREVALENCE OF PTEN IN CANCER Prevalence of PTEN deficiency and CNS metastases in major cancers • First in Class opportunity: Currently no FDA-approved Approximate frequency of Est. CNS Metastases Cancer type treatments for PTEN-mutant cancers PTEN loss Prevalence L
Slide 10: kt-5000AI: Poster Highlights from Society of Neuro-Oncology Meeting
kt-5000AI : ATR/mTOR INHIBITOR AI Design POSTER HIGHLIGHTS FROM SOCIETY OF NEURO-ONCOLOGY MEETING – NOV 2025 Validation Lead Selection Oral, potent, ATR/mTOR inhibitor with CNS penetration TSX.V: RKV / FSE: 7JO0 10
Slide 11: kt-5000AI: Summary & Next Steps
kt-5000AI : ATR/mTOR INHIBITOR SUMMARY & NEXT STEPS AI-driven drug discovery has the potential to streamline the identification of new best-in-class drug candidates for the treatment of many diseases, $5.5B Estimated ATR inhibitor market in 2033 including cancer. • 2025 The Enki generative AI plat
Slide 12: kt-2000AI: PARP1 Inhibitor
kt-2000AI : PARP1 INHIBITOR A CNS PENETRANT SELECTIVE INHIBITOR OF PARP1 • Poly(ADP ribose) polymerase (PARP) is a key enzyme in DNA repair, and inhibition of PARP1 drives cancer cell death. • 1st generation PARP-1/2 inhibitors have achieved commercial success in the treatment of certain breast, ova
Slide 13: kt-2000AI: Poster Highlights from Society of Neuro-Oncology Meeting
kt-2000AI : PARP1 INHIBITOR POSTER HIGHLIGHTS FROM SOCIETY OF NEURO-ONCOLOGY MEETING – NOV 2025 TSX.V: RKV / FSE: 7JO0 13
Slide 14: kt-2000AI: Summary & Next Steps
kt-2000AI : PARP1 INHIBITOR SUMMARY & NEXT STEPS $2.3B AI-driven drug discovery has the potential to streamline the in annual revenue from first-generation PARP inhibitors identification of new best-in-class drug candidates for the treatment of many diseases, including cancer. • Billions of drug can
Slide 15: kt-3283: PARP / HDAC Inhibitor
kt-3283 : PARP / HDAC INHIBITOR A POTENTIAL BEST-IN-CLASS DUAL INHIBITOR • Poly(ADP-ribose) polymerase (PARP) and Histone deacetylases (HDACs) both play a major role in DNA repair. Combined inhibition has shown synergistic efficacy in preclinical studies in various cancers. • Rakovina’s team has dem
Slide 16: kt-3283: Poster Highlights from AACR Meeting
POSTER HIGHLIGHTS FROM AMERICAN ASSOCIATION kt-3283 : PARP / HDAC INHIBITOR OF CANCER RESEARCH MEETING – APR 2024 TSX.V: RKV / FSE: 7JO0 16
Slide 17: kt-3283: Summary & Next Steps
kt-3283 : PARP / HDAC INHIBITOR SUMMARY & NEXT STEPS • Rakovina’s data have demonstrated a potent dual inhibitor in kt-3283 with an increased potency $18B DDR annual market potential by 2030 compared to approved inhibitors olaparib or vorinostat alone • To improve delivery to the tumor site, Rakovin
Slide 18: AI Powered Drug Development
AI POWERED DRUG DEVELOPMENT Patients cannot wait years to get the treatment they need today Traditional Drug Development AI Driven Drug Development THOUSANDS of potential drug candidates BILLIONS of potential drug candidates DEVELOPMENT PATH STAGE 1 Selecting a STAGE 1 Clinical Lead STAGE 2 STAGE 2
Slide 19: Rakovina's AI Platforms: Deep Docking & Enki
RAKOVINA’S AI PLATFORMS: HOW IT WORKS DEEP DOCKINGTM & ENKITM Deep Docking and Enki are distinct computational Exclusive access to Deep modeling techniques that Docking AI platform1 for DNA- rapidly evaluate billions of damage response (DDR) targets compounds to identify novel therapeutic drug candi
Slide 20: Deep Docking AI Platform: Real-World Impact on COVID-19
DEEP DOCKING AI PLATFORM1: REAL-WORLD IMPACT ON COVID-19 The team behind Deep Docking partnered with Nvidia, Dell and UBC Advanced Research Computing (ARC) to identify potential COVID-19 therapeutics from large libraries. “Even with a supercomputer, it would take years to screen billions of compound
Slide 21: Experienced Team with a Track Record of Success
EXPERIENCED TEAM WITH A TRACK RECORD OF SUCCESS A team with deep expertise in drug discovery, preclinical and clinical development and pharma partnering KIM OISHI ARTEM CHERKASOV, PHD Chief Executive Officer SAB/Senior AI & Medicinal Chemistry Advisor • 25+ years of capital markets experience, finan
Slide 22: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Rakovina’s globally respected Scientific Advisory Board provides the strategic insight and credibility to attract partners and investors DENNIS BROWN, PHD WANG SHEN, PHD Chair, Scientific Advisory Board (SAB)/Director SAB/Senior Medicinal Chemistry Advisor • Involved in can
Slide 23: Rakovina Therapeutics' Competitive Advantage
RAKOVINA THERAPEUTICS’ COMPETITIVE ADVANTAGE WHAT SETS THIS COMPANY APART VALIDATED AI TECHNOLOGY $18B ADDRESSABLE MARKET BY 20301 Deep Docking platform developed drug licensed to Roche Broad cancer application targeting solid tumors that Pharma in 2015 for over $140M USD in largest IP deal harbor a
Slide 24: Market Summary
MARKET SUMMARY EXCHANGE TSX Venture Exchange (TSXV) OWNERSHIP SUMMARY SYMBOL RKV Edison Oncology SECTOR / INDUSTRY Biopharmaceuticals / Oncology Holding Corp. 12% YEAR HIGH / LOW CAD $2.30 / $0.085 Reporting Insiders, 4% SHARES OUTSTANDING 21,148,039 Institution / FULLY DILUTED 35,642,647 Retail 66%
Slide 25: Contact
ir@rakovinatherapeutics.com rakovinatherapeutics.com Suite 720, 999 West Broadway Vancouver, British Columbia Canada V5Z/ FSE: TSX.V: RKV 1K5 7JO0 25
Rakovina Therapeutics — Investor Presentation (February 2026) on 6ix